Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin.
Paige WeaverTsz Hin NgThomas BreedenStephanie B EdwinChristopher Alan Giulianonull nullChristopher GiulianoPublished in: The Annals of pharmacotherapy (2022)
No difference was observed in obese patients with weight >120 kg or BMI >40 kg/m<sup>2</sup> receiving rivaroxaban or warfarin for VTE treatment in hazard of VTE or major bleeding. Either agent may be considered an appropriate treatment option in this population.